| HOME >> BIOLOGY >> TECHNOLOGY |
HONG KONG, Feb. 18 /PRNewswire-Asia/ -- Obio Pharmaceutical Holdings Ltd ("Obio"/ "the Company") announced its business growth ticket to the international pharmaceutical arena. With a strong product pipeline in drug development, backed up by strong international investors including Yangtze Ventures Limited (New World Group, Shui On Group, Tai Sang Land Properties Limited, Yu Hwa Chinese Products Group, YangtzeKiang Garment Manufacturing Company Limited), Avanta Capital, Group of prominent Swiss investors, Simplex Capital Fund (Korea based), Japanese investors Mr. Haruyoshi Taguchi and Mr. Takatoshi Nakamura, PE Lifestyle (HK) Limited (subsidiary of Singapore listed company -- Goldtron Limited), Obio is taking off and adopting more aggressive measures to drive the growth of the Company.
The research based emerging pharmaceutical company has just had a facelift by appointing seasoned pharmaceutical executives to the Board so as to further overhaul its research and development activities and heighten its competitive edge. External research collaborations will continue to be the pillars of the Company to boost innovations and confirm experimental data in the future.
Mr. Abraham Chan, Director of the Company, said on the press conference of the Company dated February 9, 2009, "Obio plans to reinforce the global development strategy by focusing its researches on the globally prevalent but underserved diseases such as diabetes and influenza."
Amongst the drug candidates in the portfolio relating to the influenza virus and life-style diseases, Obio has managed to get two drugs patented at present. Drug DC9703, which targets Diabetes II, has been granted patents in USA and South Africa. The Company has also successfully patented the AK20 in China, which treats Nonalcoholic Steatohepatitis (NASH/ nonalcoholic fatty liver disease).
Besides the two patented drugs, Obio has also discovered a
'/>"/>
| SOURCE Obio Pharmaceutical Holdings Limited Copyright©2009 PR Newswire. All rights reserved |